This project characterizes the longitudinal progression of children and adults who have tested positive for one or more islet cell autoantibodies across the early stages of type 1 diabetes (T1D). Despite advances in screening, limited evidence exists on how clinical, metabolic, and immunological markers evolve over time and predict progression to symptomatic disease. Using a screened cohort, participants are followed for up to 10 years with repeated standardized assessments. The study evaluates whether population-based screening can reduce diabetic ketoacidosis (DKA) at diagnosis and identify early predictors of progression to clinical T1D. Results are expected to improve risk stratification, inform surveillance strategies, and guide the timing of preventive interventions, with implications for clinical practice and health policy.
This is a multicenter, prospective, observational study of individuals who have tested positive for one or more islet cell autoantibodies and do not have clinical diabetes at enrolment. Participants undergo longitudinal follow-up for up to 10 years in accordance with standard clinical practice. Follow-up assessments include measures of glucose metabolism (fasting plasma glucose, HbA1c, oral glucose tolerance test \[OGTT\], and C-peptide), repeated islet cell autoantibody testing, and documentation of autoimmune comorbidities. Where available, continuous glucose monitoring (CGM) may be used to detect early dysglycemia. Psychological well-being is assessed at predefined intervals using validated instruments. Data are collected and managed through a secure REDCap platform with pseudonymization and built-in quality control procedures. No experimental interventions are planned; all evaluations are performed as part of routine care. The study is approved by the National ethics committee for clinical trials of public research bodies (EPR) and other national public institutions (CEN), and written informed consent is obtained from all participants or, where applicable, from a parent or legal guardian.
Study Type
OBSERVATIONAL
Enrollment
300
SOD Diabetologia Pediatrica - Azienda Ospedaliero Universitaria delle Marche
Ancona, Italy
Ambulatorio di Diabetologia Pediatrica, UOC Pediatria/Neonatologia Ospedale San Paolo
Bari, Italy
Department of Pediatrics, Hospital of Bolzano (SABES-ASDAA),Teaching Hospital of Paracelsus Medical University
Bolzano, Italy
UOS Diabetologia ed Endocrinologia pediatrica, AORN Sant'Anna e San Sebastiano
Caserta, Italy
UOC Pediatria, Azienza Ospedaliero-Universitaria "Renato Dulbecco"
Catanzaro, Italy
Centro Provinciale di Diabetologia Pediatrica - SOC di Pediatria - Ospedale "S. Giovanni di Dio"
Crotone, Italy
SOC Diabetologia ed Endocrinologia, AOU Meyer IRCCS
Florence, Italy
Università degli Studi dell'Aquila - UO Pediatria e PSP, Ospedale San Salvatore
L’Aquila, Italy
Ospedale S. Raffaele
Milan, Italy
Centro Regionale di Diabetologia Pediatrica, UOC Pediatria Specialistica, Dipartimento ad Attività Integrata Materno Infantile, AOU Federico II
Naples, Italy
...and 14 more locations
Progression to Stage 3 Type 1 Diabetes
Proportion of participants who progress from pre-symptomatic stages (pre-stage 1, stage 1, or stage 2) to clinical stage 3 type 1 diabetes, defined according to ADA diagnostic criteria based on hyperglycemia with or without symptoms. Progression is identified using routine metabolic assessments and clinical evaluation.
Time frame: Up to 10 years from baseline for each participant.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.